Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
33.90M | 30.11M | 55.94M | 73.73M | 8.38M | Gross Profit |
8.92M | 3.68M | 12.05M | 32.43M | -3.60M | EBIT |
69.00K | -19.30M | -24.55M | 5.87M | -40.10M | EBITDA |
-15.96M | -15.75M | -19.12M | 7.87M | -19.54M | Net Income Common Stockholders |
-16.85M | -27.74M | -32.63M | 3.35M | -92.23M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
11.80M | 23.05M | 42.19M | 105.51M | 89.80M | Total Assets |
25.35M | 38.99M | 70.43M | 127.27M | 103.13M | Total Debt |
10.77M | 11.09M | 14.11M | 13.82M | 15.38M | Net Debt |
6.22M | 2.66M | -4.93M | -91.68M | -74.42M | Total Liabilities |
17.61M | 18.02M | 22.48M | 27.33M | 22.76M | Stockholders Equity |
-788.00K | 13.00M | 39.93M | 92.73M | 77.81M |
Cash Flow | Free Cash Flow | |||
-12.80M | -18.45M | -31.02M | 6.97M | -29.36M | Operating Cash Flow |
-11.01M | -16.07M | -24.19M | 15.64M | -25.01M | Investing Cash Flow |
5.89M | 5.65M | -34.84M | -6.24M | -4.35M | Financing Cash Flow |
1.36M | 8.00K | -27.38M | 6.35M | 117.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $56.93M | 0.62 | 548.07% | ― | -4.88% | ― | |
61 Neutral | $11.85M | 8.53 | 23.48% | ― | 12.93% | 66.81% | |
57 Neutral | $147.39M | 66.49 | -3.32% | ― | -39.47% | -110.28% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
47 Neutral | $7.96M | ― | -446.50% | ― | 445.72% | 84.92% | |
40 Underperform | $4.53M | ― | -797.66% | ― | 1.33% | 35.82% | |
33 Underperform | $22.72M | ― | ― | -10.33% | 79.59% |
On May 13, 2025, XWELL, Inc. received a notification from the Nasdaq Stock Market indicating that the company’s common stock did not meet the minimum bid price requirement of $1.00 per share over a 30-day period, which is necessary for continued listing on the Nasdaq Capital Market. XWELL has been given a compliance period until November 10, 2025, to meet this requirement by maintaining a minimum closing bid price of $1.00 for at least ten consecutive business days. If XWELL fails to comply within this period, they may qualify for an additional 180-day extension if they meet other listing standards and provide a plan to address the deficiency, potentially through a reverse stock split. The letter does not immediately affect the company’s stock listing, which remains active on Nasdaq.
On April 10, 2025, XWELL held a Special Meeting where stockholders voted on five proposals. The meeting saw participation from 3,251,366 shares of common stock. Proposal 1, concerning the issuance of shares to comply with Nasdaq Listing Rule 5635(d), was authorized. Proposal 2, aimed at classifying the board of directors into two classes, was not approved. Proposal 3, which involved amending the Incentive Plan to increase the number of shares available for awards, was approved. Proposal 4, the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for 2025, was ratified. Lastly, Proposal 5, to adjourn the meeting if necessary, was also approved.
On March 13, 2025, XWELL, Inc. announced a strategic investment plan to acquire select medical spas by the end of 2025, using a $4 million private placement to expand into the wellness and beauty sector. This move aims to position XWELL as a leader in the rapidly growing market by offering advanced, personalized wellness treatments in metropolitan areas like Orlando, Austin, and Salt Lake City, thereby enhancing its brand presence and catering to the rising demand for non-invasive, results-driven beauty and wellness services.